for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Atara Biotherapeutics Inc

ATRA.OQ

Latest Trade

22.99USD

Change

-0.19(-0.82%)

Volume

192,254

Today's Range

22.61

 - 

23.29

52 Week Range

4.52

 - 

24.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
23.18
Open
23.22
Volume
192,254
3M AVG Volume
17.84
Today's High
23.29
Today's Low
22.61
52 Week High
24.00
52 Week Low
4.52
Shares Out (MIL)
77.71
Market Cap (MIL)
1,801.42
Forward P/E
-5.51
Dividend (Yield %)
--

Next Event

Atara Biotherapeutics Inc at Evercore ISI HealthCONx Conference (Virtual)

Latest Developments

More

Atara Biotherapeutics Reports Q3 Loss Per Share $0.92

Atara Biotherapeutics Announces Early-Stage Data From Multiple Sclerosis Treatment

Atara Biotherapeutics Reports Q2 Loss Per Share $1.14

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Atara Biotherapeutics Inc

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

Industry

Biotechnology & Drugs

Contact Info

611 Gateway Blvd Ste 900

SOUTH SAN FRANCISCO, CA

94080-7015

United States

+1.650.2788930

http://www.atarabio.com/

Executive Leadership

Ronald C. Renaud

Chairman of the Board

Pascal Touchon

President, Chief Executive Officer, Director

Utpal Koppikar

Chief Financial Officer

Joseph Newell

Chief Operating Officer, Executive Vice President

K. Amar Murugan

Senior Vice President, General Counsel

Key Stats

2.00 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-4.000

2018

-5.270

2019

-5.670

2020(E)

-4.208
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
5.06
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-86.36
Return on Equity (TTM)
-78.88

Latest News

Latest News

BRIEF-Atara Biotherapeutics Says First Patient Enrolled In Randomized Placebo-Controlled Study Of Allogeneic T-Cell Therapy ATA188

* ATARA BIOTHERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN RANDOMIZED PLACEBO-CONTROLLED STUDY OF ALLOGENEIC T-CELL THERAPY ATA188 IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS Source text for Eikon: Further company coverage:

BRIEF-Atara Biotherapeutics Announces Its 2020 Annual Meeting Of Stockholders Will Be Held On June 16, 2020 In Virtual Format

* ATARA BIOTHERAPEUTICS ANNOUNCES ITS 2020 ANNUAL MEETING OF STOCKHOLDERS WILL BE HELD ON JUNE 16, 2020 IN VIRTUAL FORMAT Source text for Eikon: Further company coverage:

BRIEF-Atara Biotherapeutics Announces Pricing Of $175.5 Million Public Offering

* ATARA BIOTHERAPEUTICS ANNOUNCES PRICING OF $175.5 MILLION PUBLIC OFFERING

BRIEF-Atara Biotherapeutics Announces Proposed Offering Of Common Stock And Pre-Funded Warrants

* ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS Source text for Eikon: Further company coverage:

BRIEF-Atara Biotherapeutics Believes It Remains On Track To Initiate A Tab-cel BLA Submission For Patients With EBV+ Ptld In Second Half Of 2020

* ATARA BIOTHERAPEUTICS INC - BELIEVES IT REMAINS ON TRACK TO INITIATE A TAB-CEL BLA SUBMISSION FOR PATIENTS WITH EBV+ PTLD IN SECOND HALF OF 2020

BRIEF-Atara Biotherapeutics Qtrly Loss Per Share $1.36

* ATARA BIOTHERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND RECENT CLINICAL, OPERATIONAL AND STRATEGIC PROGRESS

BRIEF-Atara Biotherapeutics Appoints Pascal Touchon As Chief Executive Officer

* ATARA BIOTHERAPEUTICS APPOINTS PASCAL TOUCHON PRESIDENT, CHIEF EXECUTIVE OFFICER AND MEMBER OF THE BOARD OF DIRECTORS

BRIEF-Atara Biotherapeutics Reports Q1 Loss Per Share $1.05

* ATARA BIOTHERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS

BRIEF-Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration

* ATARA BIOTHERAPEUTICS EXPANDS T-CELL IMMUNOTHERAPY COLLABORATION TO ADVANCE NEXT-GENERATION CAR T TECHNOLOGIES IN ONCOLOGY, AUTOIMMUNE AND OTHER DISEASES Source text for Eikon: Further company coverage:

BRIEF-Atara Biotherapeutics prices public offering of stock at $35 per share​

* ATARA BIOTHERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Atara Biotherapeutics Files For Potential Mixed Shelf Offering

* ATARA BIOTHERAPEUTICS INC FILES FOR A POTENTIAL MIXED SHELF OFFERING; SIZE UNDISCLOSED - SEC FILING Source text (http://bit.ly/2CKPbcB) Further company coverage:

BRIEF-Atara Says Commenced Underwritten Public Offering Of $150 Mln Shares Of Common Stock

* ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

BRIEF-Atara Biotherapeutics Posts Q4 Loss Of $1.15 Per Share

* ATARA BIOTHERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS

BRIEF-Atara Biotherapeutics Says CFO Intends To Retire In April 2018

* ATARA BIOTHERAPEUTICS ANNOUNCES CHIEF FINANCIAL OFFICER INTENTION TO RETIRE IN APRIL 2018

BRIEF-Atara Biotherapeutics Gets FDA Clearance To Proceed With Multiple Sclerosis study

* ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO PROCEED WITH ENROLLMENT AT U.S. SITES FOR ONGOING GLOBAL PHASE 1 CLINICAL STUDY TO EVALUATE ATA188 IN PATIENTS WITH PROGRESSIVE OR RELAPSING-REMITTING MULTIPLE SCLEROSIS

BRIEF-Camber Capital Management Reports 6.7 Pct Passive Stake In Atara Biotherapeutics

* CAMBER CAPITAL MANAGEMENT LLC REPORTS A 6.7 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS AS OF JANUARY 04 - SEC FILING Source text : ( http://bit.ly/2m1PfiG ) Further company coverage:

BRIEF-Atara Biotherapeutics Announces Proposed Offering Of Common Stock

* ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

BRIEF-Atara Biotherapeutics Gets FDA Clearance To Initiate Two Phase 3 Clinical Studies To Evaluate Tabelecleucel

* ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO INITIATE TWO PHASE 3 CLINICAL STUDIES TO EVALUATE TABELECLEUCEL IN PATIENTS WITH RITUXIMAB-REFRACTORY EPSTEIN-BARR VIRUS ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (EBV+PTLD)

BRIEF-Morgan Stanley Reports 5 Pct Passive Stake In Atara Biotherapeutics As Of Nov 27

* MORGAN STANLEY REPORTS 5.0 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS INC AS OF NOVEMBER 27 - SEC FILING Source text: (http://bit.ly/2jrEZiq) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up